The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial
Open accessAbstract
Recurrent hepatic encephalopathy (HE) is a leading cause of readmission despite standard of care (SOC) associated with microbial dysbiosis. Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it has not been studied in HE. We aimed to define whether FMT using a rationally derived stool donor is safe in recurrent HE compared to SOC alone. An open‐label, randomized clinical trial with a 5‐month follow‐up in outpatient men with cirrhosis with recurrent HE on SOC was conducted with 1:1 randomization. FMT‐randomized patients received 5 days of broad‐spectrum antibiotic pretreatment, then a single FMT enema from the same donor with the optimal microbiota deficient in HE. Follow‐up occurred on days 5, 6, 12, 35, and 150 postrandomization. The primary outcome was safety of FMT compared to SOC using FMT‐related serious adverse events (SAEs). Secondary outcomes were adverse events, cognition, microbiota, and metabolomic changes. Participants in both arms were similar on all baseline criteria and were followed until study end. FMT with antibiotic pretreatment was well tolerated. Eight (80%) SOC participants had a total of 11 SAEs compared to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02). Five SOC and no FMT participants developed further HE ( P = 0.03). Cognition improved in the FMT, but not the SOC, group. Model for End‐Stage Liver Disease (MELD) score transiently worsened postantibiotics, but reverted to baseline post‐FMT. Postantibiotics, beneficial taxa, and microbial diversity reduction occurred with Proteobacteria expansion. However, FMT increased diversity and beneficial taxa. SOC microbiota and MELD score remained similar throughout. Conclusion: FMT from a rationally selected donor reduced hospitalizations, improved cognition, and dysbiosis in cirrhosis with recurrent HE. (H epatology 2017;66:1727–1738)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“Microbiota relative abundance was analyzed using UNIFRAC, principal component analysis (PCA), and linear discriminant analysis effect size (LEFSe) between and within groups and also compared to the donor.((27,28)) The microbiota analysis was divided in the FMT groups into baseline versus postantibiotics (day 0 vs.”
MethodMetagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Malinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., & ter Borg, P. C. J. (2000) · Hepatology · doi:10.1053/he.2000.5852 · Cited by 2,893 · cited 1×
“Participants underwent screening procedures including complete blood count, Model for End-Stage Liver Disease (MELD) calculation,((22)) stool analysis for Clostridium difficile and a 24-hour dietary recall.”
MethodColonic Health: Fermentation and Short Chain Fatty Acids
Wong, J. M. W., de Souza, R., Kendall, C. W. C., Emam, A., & Jenkins, D. J. A. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00015 · Cited by 2,739
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014) · Hepatology · doi:10.1002/hep.27210 · Cited by 2,056
Self-citationMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Self-citationThe microbiology of butyrate formation in the human colon
Pryde, S. E., Duncan, S. H., Hold, G. L., Stewart, C. S., & Flint, H. J. (2002) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2002.tb11467.x · Cited by 1,320
Reichardt, N., Duncan, S. H., Young, P., Belenguer, A., McWilliam Leitch, C., Scott, K. P., Flint, H. J., & Louis, P. (2014) · The ISME Journal · doi:10.1038/ismej.2014.14 · Cited by 1,289
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Alcohol, liver disease and the gut microbiota
Bajaj, J. S. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0099-1 · Cited by 697
Self-citationMilosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551
Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Self-citationContribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Chopyk, D. M., & Grakoui, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.077 · Cited by 490
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
Rose, C. F., Amodio, P., Bajaj, J. S., Dhiman, R. K., Montagnese, S., Taylor-Robinson, S. D., Vilstrup, H., & Jalan, R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.013 · Cited by 470
Self-citationEASL Clinical Practice Guidelines on the management of hepatic encephalopathy
Montagnese, S., Rautou, P.-E., Romero-Gómez, M., Larsen, F. S., Shawcross, D. L., Thabut, D., Vilstrup, H., & Weissenborn, K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.001 · Cited by 440
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
The Super-Donor Phenomenon in Fecal Microbiota Transplantation
Wilson, B. C., Vatanen, T., Cutfield, W. S., & O'Sullivan, J. M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00002 · Cited by 413
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Clinical Application and Potential of Fecal Microbiota Transplantation
Ooijevaar, R. E., Terveer, E. M., Verspaget, H. W., Kuijper, E. J., & Keller, J. J. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-111717-122956 · Cited by 336
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
Fecal microbiota transplantation in cancer management: Current status and perspectives
Chen, D., Wu, J., Jin, D., Wang, B., & Cao, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32003 · Cited by 321
Microbiota transplantation: Concept, methodology and strategy for its modernization
FMT-standardization Study Group, Zhang, F., Cui, B., He, X., Nie, Y., Wu, K., & Fan, D. (2018) · Protein & Cell · doi:10.1007/s13238-018-0541-8 · Cited by 300
Bajaj, J. S., Salzman, N. H., Acharya, C., Sterling, R. K., White, M. B., Gavis, E. A., Fagan, A., Hayward, M., Holtz, M. L., Matherly, S., et al. (2019) · Hepatology · doi:10.1002/hep.30690 · Cited by 295
Self-citationVallianou, N., Christodoulatos, G. S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., & Dalamaga, M. (2021) · Biomolecules · doi:10.3390/biom12010056 · Cited by 289
The microbiota in cirrhosis and its role in hepatic decompensation
Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 268
Self-citationHou, H., Chen, D., Zhang, K., Zhang, W., Liu, T., Wang, S., Dai, X., Wang, B., Zhong, W., & Cao, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.11.027 · Cited by 263
A randomized clinical trial of fecal microbiota transplant for alcohol use disorder
Bajaj, J. S., Gavis, E. A., Fagan, A., Wade, J. B., Thacker, L. R., Fuchs, M., Patel, S., Davis, B., Meador, J., Puri, P., et al. (2021) · Hepatology · doi:10.1002/hep.31496 · Cited by 262
Self-citationZhang, T., Lu, G., Zhao, Z., Liu, Y., Shen, Q., Li, P., Chen, Y., Yin, H., Wang, H., Marcella, C., et al. (2020) · Protein & Cell · doi:10.1007/s13238-019-00684-8 · Cited by 260
Microbiota, cirrhosis, and the emerging oral-gut-liver axis
Acharya, C., Sahingur, S. E., & Bajaj, J. S. (2017) · JCI Insight · doi:10.1172/jci.insight.94416 · Cited by 256
Self-citationMicrobiome as a therapeutic target in alcohol-related liver disease
Sarin, S. K., Pande, A., & Schnabl, B. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.019 · Cited by 253
Marcella, C., Cui, B., Kelly, C. R., Ianiro, G., Cammarota, G., & Zhang, F. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16148 · Cited by 250
Crosstalk between the microbiota-gut-brain axis and depression
Du, Y., Gao, X.-R., Peng, L., & Ge, J.-F. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04097 · Cited by 191
“This microbial profile is associated with cognitive impairment and systemic inflammation, which can predict negative outcomes [24].”
BackgroundGut–Liver Axis: How Do Gut Bacteria Influence the Liver?
Konturek, P. C., Harsch, I. A., Konturek, K., Schink, M., Konturek, T., Neurath, M. F., & Zopf, Y. (2018) · Medical Sciences · doi:10.3390/medsci6030079 · Cited by 168
Fecal microbiota transplantation beyond Clostridioides difficile infections
Wortelboer, K., Nieuwdorp, M., & Herrema, H. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.066 · Cited by 163
Recipient factors in faecal microbiota transplantation: one stool does not fit all
Danne, C., Rolhion, N., & Sokol, H. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00441-5 · Cited by 154
Sung, C. M., Lin, Y.-F., Chen, K.-F., Ke, H.-M., Huang, H.-Y., Gong, Y.-N., Tsai, W.-S., You, J.-F., Lu, M. J., Cheng, H.-T., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.008 · Cited by 127
Promises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Self-citationNardelli, S., Gioia, S., Ridola, L., Farcomeni, A., Merli, M., & Riggio, O. (2019) · Hepatology · doi:10.1002/hep.30304 · Cited by 109
Microbiota, a key player in alcoholic liver disease
Cassard, A.-M., & Ciocan, D. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0067 · Cited by 100
Xie, W.-R., Yang, X.-Y., Xia, H. H.-X., Wu, L.-H., & He, X.-X. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i19.3074 · Cited by 67
Gut microbiota and epilepsy: a systematic review on their relationship and possible therapeutics
Arulsamy, A., Tan, Q. Y., Balasubramaniam, V., O’Brien, T. J., & Shaikh, M. F. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00431 · Cited by 65
McQuade, J. L., Ologun, G. O., Arora, R., & Wargo, J. A. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00913-y · Cited by 63
Kazemian, N., Ramezankhani, M., Sehgal, A., Khalid, F. M., Kalkhoran, A. H. Z., Narayan, A., Wong, G. K.-S., Kao, D., & Pakpour, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-75162-x · Cited by 61
Kronsten, V. T., & Shawcross, D. L. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114437 · Cited by 27
Human gut microbiome: the hypothesis of a gut-muscle axis in the elderly
Ticinesi, A., Tana, C., Nouvenne, A., & Meschi, T. (2018) · Deutsche Zeitschrift für Sportmedizin · doi:10.5960/dzsm.2018.355 · Cited by 4
Metadata
- Authors
- Bajaj, J. S., Kassam, Z., Fagan, A., Gavis, E. A., Liu, E., Cox, I. J., Kheradman, R., Heuman, D., Wang, J., Gurry, T., Williams, R., Sikaroodi, M., Fuchs, M., Alm, E., John, B., Thacker, L. R., Riva, A., Smith, M., Taylor‐Robinson, S. D., & Gillevet, P. M.
- Venue
- Hepatology
- Published
- 2017-10-30
- Volume
- 66
- Issue
- 6
- Pages
- 1727-1738
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2623146054
- Cited by
- 633
- References
- 48
- FWCI
- 36.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.